A new study reveals that Mcl-1 protein is essential for the survival of hematopoietic stem cells (HSCs), which can contribute to poor leukemia outcomes. The research suggests that interfering with this protein may improve leukemia treatment options.
The level of signal-joint TRECs (sjTRECs) in the blood appears to directly reflect the ability of the transplant recipient's thymus gland to process donated stem cells. High levels of sjTRECs indicate a successful reconstitution of the T cell population, improving patient outcomes.
The St. Jude team determined the shape of CbpA, a large protein used by Streptococcus pneumoniae bacteria to invade human cells. This discovery will guide researchers in developing a new vaccine that can trigger production of antibodies against the CbpA protein.
The guidelines provide recommendations for screening and management of late effects in pediatric cancer survivors, aiming to improve adult quality of life. The report authors anticipate that widespread use will help researchers determine the efficacy of screening survivors to reduce medical complications and death.
Researchers have developed a new mouse model of Leber congenital amaurosis, a rare form of childhood blindness. The model, which lacks the AIPL1 gene, closely mimics the inherited human disease and shows severe retinal degeneration starting around two weeks of life.
A three-week treatment with methylphenidate improved the attention and behavioral problems of children who survived childhood cancer, including leukemia and brain tumors. The study suggests that this treatment may help resolve some of the serious side effects of cancer treatment in these children.
Researchers at St. Jude Children's Research Hospital found that white matter lesions caused by treatment can mimic cancer, leading to unnecessary treatment. The study also linked WMLs to a decline in neurocognitive function in children with brain tumors.
The program will test 10-15 drugs or drug combinations per year to identify promising agents for childhood cancer treatment. It uses preclinical models and genetically engineered lines to predict activity and extends previous research by testing a broader spectrum of anticancer agents.
A St. Jude clinical trial has shown promising results in treating acute lymphoblastic leukemia with a new chemotherapy regimen that eliminates irradiation, achieving high event-free survival rates of over 80% and overall survival rates of around 86%. The trial's stringent risk classification and early intensification of chemotherapy le...
A study by St. Jude, Loyola and Kyoto University discovered that XBP1 coordinates the processes of building and equipping new ER to increase the cell's capacity for folding and shipping proteins. The gene triggers the production of phosphatidylcholine, a major building block of the ER membranes.
The Lag-3 gene controls regulatory T-cell function, which can prevent autoimmune diseases but also inhibit anti-cancer immune attacks. Researchers found that manipulating Lag-3 levels on T cells might prevent autoimmune diseases or amplify immune system attacks on cancer cells.
A study by St. Jude Children's Research Hospital found that sustained exercise can prevent cell death in the substantia nigra of adult mice treated with a toxin called MPTP, which mimics Parkinson's disease. Exercise increased production of glial-derived neurotrophic factor (GDNF), protecting nerves against damage caused by free radicals.
Researchers at St. Jude Children's Research Hospital developed a gene vector that allows hematopoietic stem cells to produce fetal hemoglobin, reversing beta-thalassemia in mice. The technique uses a new vector with added regulatory elements to improve the expression of the gamma-globin gene.
A study by St. Jude Children's Research Hospital found that the protein Mrp4 limits penetration of topotecan into the brain, which could improve treatment for brain cancer. Over-expression of Mrp4 in tumors contributes to topotecan resistance in patients.
A retrospective study from St. Jude Children's Research Hospital found that high levels of telomerase gene expression are associated with an unfavorable outcome for children treated for osteosarcoma, including lower progression-free survival rates and decreased overall survival.
Researchers at St. Jude Children's Research Hospital have uncovered the structure of an enzyme that produces folate, a nutrient essential for bacterial survival. The team created images of the molecular structure using X-ray crystallography and discovered a new target for drugs that could avoid antibiotic resistance in anthrax bacteria.
Researchers at St. Jude Children's Research Hospital have successfully treated medulloblastoma brain cancer in lab models by targeting a single protein in the hedgehog pathway, demonstrating potential for novel treatment approaches and improved outcomes for patients.
Researchers at St. Jude Children's Research Hospital have discovered the structure and function of the 'tail' of a protein essential for cell replication, revealing potential targets for new anticancer drugs. The study found that a slight modification in the protein's shape can create unique enzyme activity.
GM1 gangliosidosis causes brain cells to self-destruct due to excessive accumulation of fatty molecules in lysosomes and disrupted protein folding. The St. Jude team found that the endoplasmic reticulum is triggered by GM1 accumulation, leading to a cell's emergency response and eventual death.
A new pediatric croup vaccine has been shown to be safe and well-tolerated in adults, with no significant reactions or laboratory abnormalities. The vaccine contains a live virus that stimulates both antibody and cellular immune responses, providing potential durable protection against hPIV-1.
A blood stem cell has been found to give rise to bone in mice, suggesting a potential basis for treatments to repair or restore bone. The study used retroviral integration site analysis to prove that a single type of stem cell can produce two distinct bodily tissues.
A defect in blood vessel formation due to the LBP-1a gene mutation can lead to growth retardation, spontaneous abortion, and infant death. The study found that embryos lacking LPB-1a had abnormally large and thin blood vessels, preventing nutrient exchange with the mother's blood.
A study published in the Journal of Clinical Oncology found that 3D radiation therapy can effectively treat brain cancer in children without impairing cognitive development. The research suggests that radiation therapy can be a viable treatment option for young children, offering hope to families affected by this type of cancer.
Researchers found four groups of genes with distinct expression patterns in leukemia cells sensitive or resistant to specific drugs, significantly related to treatment outcome. The study identified 123 previously unrecognized genes associated with drug resistance, representing potential targets for new agents.
A new study reveals gene microarray technology can accurately diagnose acute myeloid leukemia subtypes, leading to better treatments. The signatures of gene expression identified in pediatric leukemias also apply to adult cases, improving diagnosis and treatment outcomes.
A study by St. Jude Children's Research Hospital found that Asian bird flu viruses, such as H5N1, became highly pathogenic through continued circulation and gene swapping in domestic ducks in southern China. The researchers warn that control of poultry outbreaks is crucial to prevent the virus from evolving into a human pandemic.
Researchers developed a reliable animal model to test new drugs for retinoblastoma, a deadly childhood cancer. The model has already identified a promising new treatment being studied in clinical trials.
Pharmacogenomics has the potential to improve health outcomes and reduce costs by identifying genes that govern drug responses. However, conducting clinical trials with pharmacogenomic studies poses challenges due to multiple genetic influences and interactions with other drugs.
A decade-long study found improved five-year, event-free survival rates of 63% in Recife, Brazil, compared to the US and Europe. The increase was attributed to adapted St. Jude treatments and supportive care, including housing and travel subsidies for families.
Researchers found that blocking a molecule that rid cells of potentially toxic molecules may make chemotherapy for leukemia more effective but also leaves healthy stem cells vulnerable. The study discovered that a protective molecule called BCRP helps protect hematopoietic stem cells from excess heme, which is toxic to cells.
Scientists have developed a 3D image of the UvsW enzyme, crucial for understanding replication-dependent replication in human cells. The findings reveal how this enzyme orchestrates the process by which viruses, plants and animals introduce new genes into DNA during replication.
Genetic studies of leukemia patients have led to the identification of specific gene mutations linked to treatment responses and drug resistance. This information is guiding the development of new drugs targeting specific cell molecules, reducing toxic side effects.
Researchers at St. Jude Children's Research Hospital developed a genetic trick adapted from viruses to create gene therapy vectors that can efficiently produce multiple proteins in specific amounts. This technique uses self-cleaving peptides to break down long protein complexes into smaller, functional proteins.
The study found that protein p27 uses flexible arms to bind to the Cdk2-cyclin A complex, which is crucial for regulating cell division and preventing cancer. The researchers discovered how proteins like p27 can identify and bind to different types of complexes, allowing them to regulate various cellular processes.
A pilot study demonstrates that detecting the presence of the ERBB2 protein in medulloblastoma tumor samples can help predict which children with medulloblastoma will require more intensive treatment. This knowledge can aid in minimizing lasting effects of therapy and increasing survival rates.
The study reveals Rb protein is crucial for retinal cell proliferation and rod development, providing clues to improving treatment of retinoblastoma. Understanding Rb's role in normal mouse development can help explain why mice without the gene don't develop the disease.
A new study by St. Jude/Mayo Clinic researchers found a direct link between the CBP gene and lymphoma development in mice, with the loss of CBP promoting T-cell lymphoma and cooperating with reduced p27Kip1 protein levels. The study suggests that CBP plays a role in cancer development despite normal p53 activity.
Researchers discovered that Ozz-E3 ligase is essential for the correct assembly of sarcomeres, which disrupts muscle formation. The study also found a close link between PPCA and Ozz genes, potentially explaining why some children with severe neurodegenerative disease suffer from muscle disorders.
The study found that vinculin changes its shape in response to protein binding, enabling it to regulate cell movement and adhesion. This versatile protein plays a critical role in both healthy development and disease progression, including cancer cell spread.
St. Jude scientists have discovered a new method to target the Topoisomerase 1 enzyme, crucial for cell division, leading to potential novel anti-cancer drugs that can work in combination with existing agents. This approach may also reduce cancer cells' ability to become resistant to treatment.
St. Jude experts highlight US vaccine production inadequacies and antiviral drug scarcity in responding to an outbreak, emphasizing the need for new technologies, international cooperation, and rapid testing.
A study by St. Jude Children's Research Hospital found that the anti-cancer drug CCI-779 can prevent abnormal brain growth and reverse seizures in lab mice lacking the Pten gene. The researchers used a mouse model to demonstrate that mTor plays multiple roles in the brain, driving cell growth and signaling pathways.
Researchers at St. Jude Children's Research Hospital have discovered that PUMA is the primary mediator of cell death in response to p53 signals, leading to apoptosis in cancer cells. The study provides critical insights into how cancer disrupts a failsafe mechanism that kills abnormal cells, and offers potential new therapy targets.
Researchers at St. Jude Children's Research Hospital have developed a new gene profiling technique that could simplify diagnostic tests for acute lymphoblastic leukemia (ALL), a childhood cancer with an 80% success rate due to risk-adapted therapy.
A new study by St. Jude Children's Research Hospital found that black children with acute lymphoblastic leukemia (ALL) can achieve high cure rates comparable to those of white children, contradicting previous clinical studies. The research suggests that personalized risk-directed therapy played a key role in overcoming disparities in t...
A recent study found that most adult childhood cancer survivors (10.9%) reported fair or poor health, despite 43.6% reporting some impairment from treatment. Factors associated with health problems were the same as those in the general population, including being female and having limited education.
In Honduras, abandonment of therapy and fatal infections lead to high mortality rates among children with ALL, but can be corrected with interventions such as transportation funding and education programs. The study found that improving survival rates requires a two-pronged approach, also addressing infection and overcrowding issues.
Researchers found that the abnormally active Bcl10 gene drives B cells to become cancerous, suggesting a drug blocking the gene could be effective treatment for MALT lymphoma. The study also showed that mice lacking Bcl10 genes cannot launch an effective antibody response against bacteria.
A long-term follow-up study of childhood ALL survivors found that those who did not receive brain radiation had comparable survival rates, employment, and marital rates to the general population. However, those who received brain radiation had a slight increase in death rate due to second cancer and higher unemployment rates.
The FDA has approved a safety trial for the second component of a three-part HIV vaccine developed at St. Jude Children's Research Hospital. The vaccine aims to overcome viral diversity with a multi-envelope approach, and includes three components: DNA, genetically modified vaccinia virus, and purified HIV envelope protein.